Big deal for AI-powered longevity biotechnology

The new collaboration is an indication of research into aging biomarkers together with the interventions discovered over the past five years is advancing. The collaboration is through the startup Napa Therapeutics, Ltd. Napa is to develop drugs against a novel aging-related target, as Business Insider reports. In terms of what each company will offer, the Buck Institute is one of the primary research centers focused on research into aging and the elimination of age-related disease. Insilico Medicine is an artificial intelligence pioneer, which is looking at on a range of factors associated with aging.